Mycoplasma pneumoniae is a major cause of respiratory infections and a possible etiology of acute hepatitis. Acute hepatitis due to M. pneumoniae infection is often combined with presentation of pneumonia, even without lung involvement. The presentations and etiologies of M. pneumoniae-associated hepatitis with simultaneous, delayed, or without, lung involvement are different, and should be discussed separately. The most widely available and effective drug of treatment is macrolides, and its clinical outcome is extremely good.
M. pneumoniae infection is transmitted through aerosols from person to person, and persons with active mycoplasmal infection will carry the organism in the nose, throat, trachea and sputum. Most M. pneumoniae infections in adults involve the respiratory tract, and symptoms range from nonproductive cough to severe pneumonia [5] . The severity of disease appears to be related to the degree to which the host immune response reacts to the infection [4] .
Extrapulmonary manifestations of M. pneumoniae infection may be found in the dermatologic, cardiovascular, neurologic, hematologic, musculoskeletal and gastrointestinal systems [6] . Approximately 25% of patients hospitalized for treatment of M. pneumoniae can present extrapulmonary complications at some time during the disease course [7] .
Skin lesions include maculopapular rashes, erythema multiforme minor, and Stevens-Johnson syndrome. Cardiovascular involvement includes myocarditis, pericarditis and rheumatic fever-like syndrome. Neurologic complications include meningoencephalitis, aseptic meningitis, cerebellar ataxia and Guillain-Barre syndrome. Hematologic involvement includes hemolysis with positive Coombs' test and reticulocytosis. Musculoskeletal presentations include nonspecific myalgia, arthralgias and polyarthropathies. Gastrointestinal manifestations include vomiting, abdominal pain, and albeit rare, pancreatitis and hepatitis [7, 8] . The immune-mediated damage by cross-reactive anti-M. pneumoniae antibodies is thought to be responsible for most of the extrapulmonary manifestations [9] .
Simultaneous M. pneumoniae-associated pneumonia and acute hepatitis
Introduction
Mycoplasma pneumoniae, one of the smallest organisms that can survive alone in nature, is a common cause of upper respiratory tract infections. The first mycoplasmas were discovered in 1898 by Nocard and Roux in animals with contagious bovine pleuropneumonia. In 1944, Eaton isolated a pathogenic Mycoplasma from a patient with atypical pneumonia. It was named M. pneumoniae by Chanock in 1962 [1] .
of M. pneumoniae acting on lymphocytes, which plays a role in the development of complications involving target organs [6] .
Suzuyama et al. [8] decumented that inflammatory signs such as higher body temperature, greater number of leukocytes, and elevated C-reactive protein (CRP) levels were more likely to appear in patients with abnormal liver function than those with normal liver function [8] . Doxboeck et al. [12] noted that patients with M. pneumoniae-associated pneumonia and abnormal liver function had higher leukocyte and CRP levels than those with normal liver function [12] . Shin et al. [13] found male gender, younger age, and higher CRP were associated with M. pneumoniae-related hepatitis [13] . In summary, patients with simultaneous pneumonia and hepatitis due to M. pneumoniae infection have greater disease severity and more acute inflammatory reactions.
M. pneumoniae-associated acute hepatitis without pneumonia
Viral hepatitis accounts for most cases of acute hepatitis. Some bacterial infections are often associated with acute hepatitis, such as Salmonella, Rickettsia, Brucella or M. pneumonia [14] . Hepatitis due to M. pneumoniae was first described in 1975 [15] . Selected cases of M. pneumoniae-associated acute hepatitis were retrieved from MEDLINE and are summarized in Table 1 [9, 14, 16, 17] . In general, acute hepatitis due to M. pneumoniae without lung infection has been largely documented in children with a cholesteric pattern [9, 10] . Hyperbilirubinemia usually occurs as the indirect type, mostly because of hemolysis in mycoplasma infections. In contrast, adults with M. pneumoniae infection have demonstrated a hepatocellular pattern of liver enzymes without jaundice [14] [15] [16] [17] .
According to these reports, the fever of individuals with M. pneumoniae subsided rapidly, on average in 1 to 2 weeks after treatment, but ALT did not normalize till about one month later. The persistent ALT elevation may be mediated by immunological mechanisms, such as cross-reactive antibodies induced by M. pneumoniae interacting with sialyloligosaccharides on hepatic cells [19] . The outcomes of these cases were extremely good, and no mortality was reported.
In children, M. pneumoniae has been reported to be implicated in infectious mononucleosis or Kawasaki disease with hepatic manifestations [16, 20] .
Delayed acute hepatitis after acute M. pneumoniae infection
On the basis of previous reports, the delayed onset of liver injury after M. pneumoniae infection was largely due to the use of treatment drugs [21] . The time course of liver injury has been reported to be 5 to 10 days. The association of macrolide antibiotics with cholestatic hepatitis is well-known [22] , and azithromycin-induced hepatotoxicity has also been reported in adults [23] .
Diagnosis
Because M. pneumoniae is an intracellular pathogen, cultures are not always available and those that are usually exhibit slow growth with low sensitivity, making them unreliable for routine diagnosis.
There is little evidence to indicate direct invasion of M. pneumonia [14] . Few previous liver pathology reports demonstrated non-specific findings, either hepatocellular destruction with inflammatory infiltration or lobular hepatitis [24, 25] . Since liver biopsy in patients with M. pneumoniae infection is usually nonspecific, it might not be necessary to confirm diagnosis.
The characteristic findings of patients with M. pneumoniaeassociated acute hepatitis with or without pneumonia are fever, elevated liver function test, positive IgM serology against M. pneumoniae followed by IgG seroconversion, with resolution by antibiotics and exclusion of other possible etiologies. It is advisable to test simultaneously for both IgM and IgG in paired specimens collected 2 to 3 weeks apart, and a fourfold or greater rise in antibody titers indicates a current or recent infection [26] .
In some adults with previous M. pneumoniae infection, longterm high seroprevalence of IgG antibodies and lack of an IgM response were observed, and that imposes serious limitations on the use of serology as the sole means for diagnosis of M. pneumoniae infection [1, 27] . Thus, a feasible approach would be to incorporate polymerase chain reaction (PCR) and the serological studies for IgG and IgM for optimum diagnosis of M. pneumoniae infections.
Treatment and Outcome
M. pneumoniae has no cell wall and therefore is naturally resistant to penicillin, cephalosporins, all beta-lactams and vancomycin, sulfonamides, trimethoprin, and rifampin. M. pneumoniae is susceptible to macrolides, cyclines, and quinolones. Interestingly, macrolides were more frequently used in patients with M. pneumoniae-associated hepatitis than quinolones. The reason might be that macrolides metabolize in the liver and are excreted primarily in the bile in contrast to quinolones which metabolize via renal excretion [28] . Up to now, no consensus on the duration of therapy with macrolides has been reached, and treatment schemes spanning from one to three weeks have been described. Clinical outcomes have been favorable in published cases, and no associated fatalities have been reported to date. However, eradication of M. pneumoniae from immunocompromised individuals can be extremely difficult, and requires prolonged therapy.
Conclusion
M. pneumoniae is a major cause of respiratory infections and a possible etiology of acute hepatitis. Acute hepatitis due to M. pneumoniae infection is often combined with presentation of pneumonia, even without lung involvement. The most widely available and effective drug of treatment is macrolides, and its clinical outcome is extremely good.
